Skip to content

Relmada Therapeutics, Inc. RLMD Business development

Business development at other companies

Piper Sandler logo
Piper SandlerPIPR
$15.15M+1.9%
Nicolet Bankshares logo
Nicolet BanksharesNIC
$2.34M+11.3%
1st Source Corporation logo
1st Source CorporationSRCE
$1.9M-1.1%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$200M0.0%
Popular logo
PopularBPOP
$22.86M-3.4%
Raymond James Financial logo
Raymond James FinancialRJF
$75M+17.2%

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:BusinessDevelopment.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s business development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s business development?
Relmada Therapeutics, Inc. (RLMD) reported business development of $200M in Q1 2026.
What does business development mean?
Expenditures or investments dedicated to strategic growth initiatives, such as licensing agreements, partnerships, or the acquisition of intellectual property. This metric indicates the company's commitment to expanding its pipeline or market reach through external collaboration.